5/17/2006 12:48:22 PM
SAN DIEGO--(BUSINESS WIRE)--May 17, 2006--Cabrellis Pharmaceuticals Corporation today announced the formal launch of operations following a successful spinout from Conforma Therapeutics Corporation. The company was formed by members of the Conforma management team that executed the sale of Conforma to Biogen Idec, Inc. earlier this month. Cabrellis is a specialty pharmaceutical company committed to the development of therapies for the treatment of cancer. The Company's lead product, Calsed(TM) (amrubicin hydrochloride), is expected to enter Phase II clinical testing later this quarter.
comments powered by